At Kinesys Consulting our
highly experienced
Principals and Expert
Panel provide support and solutions
for strategic development, regulatory and technical
challenges faced by pharmaceutical and biotechnology
companies.
The Principals
– Gerry McGettigan, Emma
Holmes, Martin Jordan and Elaine Murphy – have all held senior posts in Pharma, Biotech and Medtech
companies, in regulatory affairs, clinical development
and business development. We have all previously set
up and run successful consultancy organizations. Our
contacts with regulatory authorities, industry leaders
and venture capital firms are second to none.
How we can help you
Therapeutic and Development Experience
Our expertise extends to most drug therapeutic
areas.
The Principals and Expert
Panel have all worked on
the development and registration of innovative and
important new therapies in the areas of, for example,
oncology, metabolic diseases, CNS and anti-infectives.
We have the knowledge and experience to add value
both to extensive development programmes for broad
disease areas and to accelerated and limited programmes
for orphan or niche indications often representing
high unmet medical needs.
Types of products
Our expertise extends to
NCEs, re-profiled products, recombinant therapies,
cell therapies and stem cell agents. Our clients include
some of the largest Pharma and Biotech companies as
well as innovative start up firms.
We have also worked on combination products involving drugs and devices and complex
tissue engineered products. We typically conduct market analyses and provide
pricing & reimbursement strategies and advice in Europe for our clients.
Expert Panel
The company’s Expert Panel is composed of senior
academics, experienced industrialists and successful entrepreneurs. The Expert
Panel has been selected to bring together difficult-to-find, specialist knowledge
and expertise from respected public figures. Our Experts and Principals work
together, often representing clients and supporting their positions in negotiations
with prospective business partners and with EMA, FDA and other regulatory authorities.
This approach frequently makes the difference in securing the optimum outcome
for our clients.